GO
Loading...

Gilead Sciences Inc

More

  • Early Glance: Biotechnology companies Thursday, 19 Feb 2015 | 10:50 AM ET

    Amgen Inc. fell$. 24 or. 2 percent, to $155.54. Biogen Idec rose $3.29 or. 8 percent, to $404.41. Celgene Corp. rose $1.55 or 1.3 percent, to $119.96.

  • LOS ANGELES, Feb 19- As U.S. drugmakers face growing resistance to the high price of cutting-edge treatments, a handful of companies are working on a new payment model that rewards them for the long-term performance of their medicines. They include BioMarin Pharmaceutical Inc in San Rafael, California, and Sangamo BioSciences Inc in Richmond, California.

  • Final Glance: Biotechnology companies Wednesday, 18 Feb 2015 | 6:30 PM ET

    Amgen Inc. rose $1.54 or 1.0 percent, to $155.78. Biogen Idec rose $3.21 or. 8 percent, to $401.12. Celgene Corp. rose $2.09 or 1.8 percent, to $118.41.

  • Midday Glance: Biotechnology companies Wednesday, 18 Feb 2015 | 1:18 PM ET

    Amgen Inc. rose$. 52 or. 3 percent, to $154.76. Biogen Idec rose$. 28 or. 1 percent, to $398.19. Celgene Corp. rose $1.29 or 1.1 percent, to $117.61.

  • Early Glance: Biotechnology companies Wednesday, 18 Feb 2015 | 10:53 AM ET

    Amgen Inc. rose$. 42 or. 3 percent, to $154.66. Biogen Idec rose$. 22 or. 1 percent, to $398.13. Celgene Corp. rose$. 99 or. 9 percent, to $117.31.

  • Final Glance: Biotechnology companies Tuesday, 17 Feb 2015 | 6:09 PM ET

    Amgen Inc. rose$. 76 or. 5 percent, to $154.24. Biogen Idec rose $6.25 or 1.6 percent, to $397.91. Celgene Corp. rose$. 44 or. 4 percent, to $116.32.

  • Midday Glance: Biotechnology companies Tuesday, 17 Feb 2015 | 1:31 PM ET

    Amgen Inc. rose$. 40 or. 3 percent, to $153.88. Biogen Idec rose $7.63 or 1.9 percent, to $399.29. Celgene Corp. rose$. 19 or. 2 percent, to $116.07.

  • Early Glance: Biotechnology companies Tuesday, 17 Feb 2015 | 11:00 AM ET

    Amgen Inc. rose $1.17 or. 8 percent, to $154.65. Biogen Idec rose $4.34 or 1.1 percent, to $396.00. Celgene Corp. rose$. 95 or. 8 percent, to $116.83.

  • Feb 17- CVS Health Corp, the second-largest U.S. pharmacy chain operator, has warned that a new class of drugs being developed to lower "bad" cholesterol could cost the U.S. healthcare system as much as $150 billion per year. The new class of cholesterol drugs called PCSK9 inhibitors could be priced in the range of $7,000- $12,000 per year, CVS said.

  • Between men and women, the better investors are... Friday, 13 Feb 2015 | 7:00 AM ET

    An exclusive analysis of more than 2.5 million portfolios tracked by SigFig found that, on average, women outperformed male investors.

  • Cramer: These unexpected gems should be snapped up Tuesday, 10 Feb 2015 | 6:00 PM ET
    A bus and pedestrian pass an advertisement for the Apple iPhone 6 in north London.

    With overseas quiet on Tuesday, Jim Cramer finally was able to ignore the noise and recommends a few gem stocks that are real winners.

  • NEW YORK, Feb 10- Gilead Sciences Inc said on Tuesday it expects the number of hepatitis C patients treated in Europe with its Sovaldi drug to increase dramatically this year, and that approvals for the newer combination pill, Harvoni, could come quickly. The company, which has come under intense criticism in the United States for the high price of its treatments...

  • LONDON, Feb 10- Global health charity Medecins du Monde launched a legal challenge on Tuesday to a European patent held by U.S. drugmaker Gilead Sciences Inc which it accused of charging "exorbitant" prices for a hepatitis C drug. According to World Health Organization data, as many as 150 million people worldwide live with chronic hepatitis C infection, most of...

  • *All-Achillion combination could rival Gilead, AbbVie treatments. Achillion's shares rose as much as 19 percent to $12.85 on Monday on investor's hopes that an all-Achillion combination could be as effective as Gilead's and AbbVie Inc's current therapies. The estimated $20 billion market for hepatitis C drugs has developed at a lightning pace in recent...

  • *Qualcomm up, nears deal with China on antitrust dispute. "China is a negative and Greece is a negative, certainly Greece is something investors have lived with for a while and it's not a huge surprise," said Rick Meckler, president of investment firm LibertyView Capital Management in Jersey City, New Jersey. On Monday, European Commission President Jean-Claude...

  • *Qualcomm near deal with China on antitrust dispute, shares climb. On Monday, European Commission President Jean-Claude Juncker said Greeks should not expect the euro zone to accept the latest terms proposed by Greece. "We are seeing heightened nervousness over the Greek elections and the policies that could make or break its EU membership," said Andre Bakhos,...

  • *Qualcomm near deal with China on antitrust dispute. NEW YORK, Feb 9- U.S. stocks were poised for a lower open on Monday, on the heels of disappointing economic data out of China and signs of rising tensions surrounding Greek debt negotiations. "We are seeing heightened nervousness over the Greek elections and the policies that could make or break its EU membership,"...

  • Feb 9- Achillion Pharmaceuticals Inc said its experimental hepatitis C drug, when used in combination with Gilead Sciences Inc's Sovaldi, eradicated signs of the virus after six weeks of therapy, sending its shares up before the opening bell. If the combination of Sovaldi and Achillion's ACH-3102 continues to show this level of effectiveness, the treatment...

  • Drug price wars 'drive value': Medical exec Friday, 6 Feb 2015 | 5:21 PM ET
    Hepatitis C sufferers and supporters hold placards during a demonstration outside of US laboratory Gilead Sciences office in Madrid on February 5, 2015.

    Price cuts, which may hurt pharmaceutical margins, are fundamentally better for consumers, said Dr. Steve Miller of Express Scripts.

  • Feb 4- Investors reassessed their growth expectations for the red-hot biotechnology sector on Wednesday after Gilead Sciences Inc warned of steep drug discounts, but a number of fund managers seemed prepared to stick with the stocks. Gilead disclosed late on Tuesday that it would give health insurers and pharmacy benefit managers discounts of 46 percent on...